centered image

EMA Panel Backs Netarsudil for Elevated Intraocular Pressure

Discussion in 'Ophthalmology' started by Hadeel Abdelkariem, Sep 23, 2019.

  1. Hadeel Abdelkariem

    Hadeel Abdelkariem Golden Member

    Apr 1, 2018
    Likes Received:
    Trophy Points:
    Practicing medicine in:

    The European Medicines Agency's (EMA's) Committee for Medicinal Products for Human Use (CHMP) recommended marketing authorization for netarsudil ophthalmic solution 0.02% (Rhokiinsa; Aerie Pharmaceuticals) for the treatment of adults with glaucoma or ocular hypertension.


    The full indication is "reduction of elevated intraocular pressure (IOP) in adult patients with primary open-angle glaucoma or ocular hypertension."

    Netarsudil is a Rho kinase inhibitor that increases outflow of aqueous humor via the trabecular outflow pathway and reduces episcleral venous pressure.

    Netarsudil ophthalmic solution 0.02% will be sold as an eyedrop solution containing 200 µ/mL.

    "We are delighted that the CHMP has adopted a positive opinion for Rhokiinsa," Vicente Anido Jr, PhD, chairman and chief executive officer at Aerie, said in a company news release.

    Netarsudil ophthalmic solution 0.02% was approved by the US Food and Drug Administration December 18, 2017, and is currently marketed as Rhopressa in the United States.

    The company said it expects a decision from the European Commission in approximately 2 months; that decision will apply to all European Union member states plus Iceland, Liechtenstein, and Norway.


    Add Reply

Share This Page